Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:ruxolitinib
|
| gptkbp:approvalYear |
2011
|
| gptkbp:ATCCode |
L01EA01
|
| gptkbp:brand |
gptkb:Jakafi
gptkb:Jakavi |
| gptkbp:CASNumber |
941678-49-5
|
| gptkbp:developedBy |
gptkb:Incyte_Corporation
|
| gptkbp:eliminationHalfLife |
3 hours
|
| gptkbp:hasMolecularFormula |
C17H18N6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
INCB018424
|
| gptkbp:indication |
gptkb:myelofibrosis
gptkb:polycythemia_vera |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK1 inhibitor
JAK2 inhibitor |
| gptkbp:metabolism |
gptkb:CYP2C9
gptkb:CYP3A4 |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
97%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
dizziness headache neutropenia thrombocytopenia bruising |
| gptkbp:bfsParent |
gptkb:ruxolitinib
|
| gptkbp:bfsLayer |
6
|